Compare Gilead Sciences, Inc. (GILD) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Warner Music Group Corp — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Warner Music Group Corp trades at $28.42 (market cap $14.77B). The key difference: Gilead Sciences, Inc. is far larger — about 11.1× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (2.68%). Which is the better fit depends on your goals.
| GILD | WMG | |
|---|---|---|
Market Cap | $163.51B | $14.77B |
Sector | Health | Media |
52-Week High | $155.80 | $34.72 |
52-Week Low | $108.22 | $23.65 |
Enterprise Value | $178.05B | $18.97B |
Dividend Yield | 2.49% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Warner Music Group (WMG) trades at $27.57, down 4.1% on the day, with a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 33.71 but strong analyst sentiment, carrying a consensus price target of $40.40. Recent business developments include the acquisition of AI startup Sureel AI to strengthen intellectual property management in the AI era, as reported by TechCrunch on June 10, 2026.
The outlook presents a valuation gap between current price and analyst targets, offering potential upside. Key opportunities include streaming market share gains and AI integration, while risks involve recent earnings misses, margin compression, and a high P/B ratio of 20.02. The stock's bearish technical picture contrasts with Wall Street's predominantly bullish analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
